Amylyx Pharmaceuticals, Inc.
AMLX
Classifica tra le azioni
#4492
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Prezzo delle azioni
$27.25
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$3.42B
Variazione (1 giorno)
3.45%
Variazione (1 anno)
77.29%
Paese
US
Scambia Amylyx Pharmaceuticals, Inc. (AMLX)
Categoria
Healthcare
Rapporto P/B per Amylyx Pharmaceuticals, Inc. (AMLX)
Rapporto P/B al October 2026 TTM: 12.57
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Amylyx Pharmaceuticals, Inc., il rapporto P/B attuale (TTM) è 12.57. Alla fine del 2023, era pari a 2.28.
Storico del rapporto P/B per Amylyx Pharmaceuticals, Inc. da 2019 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | 12.57 | 705.59% |
| 2024 | 1.56 | -31.54% |
| 2023 | 2.28 | -68.35% |
| 2022 | 7.22 | -204.32% |
| 2021 | -6.92 | -54.77% |
| 2020 | -15.29 | -62.00% |
| 2019 | -40.24 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| 6.251 | -50.26% |
US
|
|
| 13.2547 | 5.47% |
US
|
|
| 4.208 | -66.52% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -50.81% |
NL
|
